| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lena H Nguyen, Travorn Mahadeo, Angélique Borde. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 39. issue 14. 2020-04-03. PMID:30700531. |
mtor hyperactivity levels influence the severity of epilepsy and associated neuropathology in an experimental model of tuberous sclerosis complex and focal cortical dysplasia. |
2020-04-03 |
2023-08-13 |
mouse |
| Ruchi Malik, Emily Ling-Lin Pai, Anna N Rubin, April M Stafford, Kartik Angara, Petros Minasi, John L Rubenstein, Vikaas S Sohal, Daniel Vog. Tsc1 represses parvalbumin expression and fast-spiking properties in somatostatin lineage cortical interneurons. Nature communications. vol 10. issue 1. 2020-03-16. PMID:31676823. |
here, we show that conditional loss of the tuberous sclerosis complex (tsc) gene, tsc1, which inhibits the mammalian target of rapamycin (mtor), causes a subset of sst+ cins, to express pv and adopt fast-spiking (fs) properties, characteristic of pv+ cins. |
2020-03-16 |
2023-08-13 |
mouse |
| Polina Kosillo, Natalie M Doig, Kamran M Ahmed, Alexander H C W Agopyan-Miu, Corinna D Wong, Lisa Conyers, Sarah Threlfell, Peter J Magill, Helen S Bateu. Tsc1-mTORC1 signaling controls striatal dopamine release and cognitive flexibility. Nature communications. vol 10. issue 1. 2020-03-02. PMID:31780742. |
tuberous sclerosis complex (tsc) is a neurodevelopmental disorder caused by mutations in tsc1 or tsc2, which encode proteins that negatively regulate mtor complex 1 (mtorc1). |
2020-03-02 |
2023-08-13 |
Not clear |
| Aishwarya G Nadadhur, Mouhamed Alsaqati, Lisa Gasparotto, Paulien Cornelissen-Steijger, Eline van Hugte, Stephanie Dooves, Adrian J Harwood, Vivi M Hein. Neuron-Glia Interactions Increase Neuronal Phenotypes in Tuberous Sclerosis Complex Patient iPSC-Derived Models. Stem cell reports. vol 12. issue 1. 2020-02-27. PMID:30581017. |
tuberous sclerosis complex (tsc) is a rare neurodevelopmental disorder resulting from autosomal dominant mutations in the tsc1 or tsc2 genes, leading to a hyperactivated mammalian target of rapamycin (mtor) pathway, and gray and white matter defects in the brain. |
2020-02-27 |
2023-08-13 |
Not clear |
| Lei Shi, Xia Chen, Aiping Zang, Tiantian Li, Yanxiang Hu, Shixin Ma, Mengdie Lü, Huiyong Yin, Haikun Wang, Xiaoming Zhang, Bei Zhang, Qibin Leng, Jinbo Yang, Hui Xia. TSC1/mTOR-controlled metabolic-epigenetic cross talk underpins DC control of CD8+ T-cell homeostasis. PLoS biology. vol 17. issue 8. 2020-02-27. PMID:31433805. |
here, we demonstrate a special metabolic-epigenetic coupling mechanism orchestrated by tuberous sclerosis complex subunit 1 (tsc1)-mechanistic target of rapamycin (mtor) for homeostatic dc function. |
2020-02-27 |
2023-08-13 |
mouse |
| Jurriaan M Peters, Anna Prohl, Kush Kapur, Audrey Nath, Benoit Scherrer, Sean Clancy, Sanjay P Prabhu, Mustafa Sahin, David Neal Franz, Simon K Warfield, Darcy A Kruege. Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. Pediatric neurology. vol 90. 2020-02-25. PMID:30424962. |
we studied the longitudinal effects of everolimus, an inhibitor of the mammalian target of rapamycin (mtor), on callosal white matter diffusion tensor imaging (dti) in patients with tuberous sclerosis complex (tsc). |
2020-02-25 |
2023-08-13 |
Not clear |
| Jeong-Seon Ryu, Jun Hyeok Lim, Hyun-Jung Kim, Min Jeong Kim, Mi Hwa Park, Jung Soo Ki. Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet. Bioscience reports. vol 39. issue 3. 2020-02-25. PMID:30842342. |
tuberous sclerosis complex (tsc) 1 and 2 function as tumor suppressors by inactivating the mammalian target of rapamycin (mtor) pathway. |
2020-02-25 |
2023-08-13 |
Not clear |
| Sam Amin, Andrew Lux, Finbar O'Callagha. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. British journal of clinical pharmacology. vol 85. issue 1. 2019-12-30. PMID:30290005. |
because of its effect on the mtor pathway, there may be a role for metformin in slowing or reversing growth of life-threatening hamartomas in tuberous sclerosis complex. |
2019-12-30 |
2023-08-13 |
human |
| Gina Hadley, Daniel J Beard, Zoi Alexopoulou, Brad A Sutherland, Alastair M Bucha. Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia. Neuroscience letters. vol 706. 2019-12-27. PMID:31100427. |
hamartin, a component of the tuberous sclerosis complex (tsc) that actively inhibits the mammalian target of rapamycin (mtor), may mediate the endogenous resistance of cornu ammonis 3 (ca3) hippocampal neurons following global cerebral ischemia. |
2019-12-27 |
2023-08-13 |
Not clear |
| Afshin Saffari, Ines Brösse, Adelheid Wiemer-Kruel, Bernd Wilken, Paula Kreuzaler, Andreas Hahn, Matthias K Bernhard, Cornelis M van Tilburg, Georg F Hoffmann, Matthias Gorenflo, Sven Hethey, Olaf Kaiser, Stefan Kölker, Robert Wagner, Olaf Witt, Andreas Merkenschlager, Andreas Möckel, Timo Roser, Jan-Ulrich Schlump, Antje Serfling, Juliane Spiegler, Till Milde, Andreas Ziegler, Steffen Syrb. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study. Orphanet journal of rare diseases. vol 14. issue 1. 2019-11-25. PMID:31053163. |
safety and efficacy of mtor inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study. |
2019-11-25 |
2023-08-13 |
Not clear |
| Nils Grabole, Jitao David Zhang, Stefan Aigner, Nadine Ruderisch, Veronica Costa, Felix C Weber, Michel Theron, Nikolaos Berntenis, Olivia Spleiss, Martin Ebeling, Gene W Yeo, Ravi Jagasia, Anna Kiialaine. Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model. Genome medicine. vol 8. issue 1. 2019-11-20. PMID:27655340. |
tuberous sclerosis complex (tsc) is a genetic disease characterized by benign tumor growths in multiple organs and neurological symptoms induced by mtor hyperfunction. |
2019-11-20 |
2023-08-13 |
human |
| Joanna Trelinska, Wojciech Fendler, Iwona Dachowska, Katarzyna Kotulska, Sergiusz Jozwiak, Karolina Antosik, Piotr Gnys, Maciej Borowiec, Wojciech Mlynarsk. Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications. Orphanet journal of rare diseases. vol 11. issue 1. 2019-11-20. PMID:27680012. |
tuberous sclerosis (tsc) is a monogenic disease resulting from defects of the tsc1 or tsc2 genes, which encode the proteins forming hamartin-tuberin tumor suppressor complex, the mammalian target of rapamycin complex (mtor). |
2019-11-20 |
2023-08-13 |
Not clear |
| Ashyad Rayhan, Adam Faller, Ryan Chevalier, Alannah Mattice, Jim Karagianni. Using genetic buffering relationships identified in fission yeast to reveal susceptibilities in cells lacking hamartin or tuberin function. Biology open. vol 7. issue 1. 2019-11-20. PMID:29343513. |
tuberous sclerosis complex is an autosomal dominant disorder characterized by benign tumors arising from the abnormal activation of mtor signaling in cells lacking tsc1 (hamartin) or tsc2 (tuberin) activity. |
2019-11-20 |
2023-08-13 |
Not clear |
| Kai-Feng Xu, Xinlun Tian, Jay H Ry. Recent advances in the management of lymphangioleiomyomatosis. F1000Research. vol 7. 2019-11-20. PMID:29946430. |
advances in our understanding of the regulatory role of tuberous sclerosis gene products (hamartin/tuberin) in the mechanistic target of rapamycin (mtor) signaling pathway have led to the identification of effective therapy (mtor inhibitors) for a rare disorder, once considered uniformly fatal. |
2019-11-20 |
2023-08-13 |
Not clear |
| Withdrawn CNS & neurological disorders drug targets. 2019-11-20. PMID:30864513. |
withdrawn loss of the pten (phosphatase and tensin homolog) gene has been demonstrated to result in hyperactivation of the mammalian target of rapamycin (mtor) pathway, a signaling pathway common to many disease etiologies, including tuberous sclerosis complex, fragile x syndrome, and schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| Yu Zhang, Hang Zhou, Yongjun Tao, Xingyu Liu, Zhu Yuan, Chunlai Ni. ARD1 contributes to IKKβ-mediated breast cancer tumorigenesis. Cell death & disease. vol 9. issue 9. 2019-11-15. PMID:30154412. |
ard1 prevents mtor activity and breast cancer cell growth by stabilizing tuberous sclerosis complex 2 (tsc2) to induce autophagy. |
2019-11-15 |
2023-08-13 |
Not clear |
| Yi Yu, Yuyan Xiong, Jean-Pierre Montani, Zhihong Yang, Xiu-Fen Min. Arginase-II activates mTORC1 through myosin-1b in vascular cell senescence and apoptosis. Cell death & disease. vol 9. issue 3. 2019-10-29. PMID:29472548. |
overexpression of arg-ii induces re-distribution of lysosome and mtor but not of tuberous sclerosis complex (tsc) from perinuclear area to cell periphery, dissociation of tsc from lysosome and activation of mtorc1-ribosomal protein s6 kinase 1 (s6k1) pathway. |
2019-10-29 |
2023-08-13 |
Not clear |
| Yusuke Umegaki, Antonio Martínez Brotons, Yui Nakanishi, Zhongyue Luo, Hanlu Zhang, Azad Bonni, Yoshiho Ikeuch. Palladin Is a Neuron-Specific Translational Target of mTOR Signaling That Regulates Axon Morphogenesis. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 38. issue 21. 2019-10-22. PMID:29712777. |
knockdown of palladin eliminated supernumerary axons induced by suppression of the tuberous sclerosis complex protein tsc1 in neurons, demonstrating that palladin regulates neuronal morphogenesis downstream of mtor signaling. |
2019-10-22 |
2023-08-13 |
mouse |
| Susana Boronat, Ignasi Barbe. Less common manifestations in TSC. American journal of medical genetics. Part C, Seminars in medical genetics. vol 178. issue 3. 2019-09-27. PMID:30156054. |
tuberous sclerosis complex (tsc) is due to pathogenic variants in tsc1 or tsc2 genes resulting in hyperactivation of the mtor pathway. |
2019-09-27 |
2023-08-13 |
Not clear |
| Derek S Lu, Patrick J Karas, Darcy A Krueger, Howard L Weine. Central nervous system manifestations of tuberous sclerosis complex. American journal of medical genetics. Part C, Seminars in medical genetics. vol 178. issue 3. 2019-09-27. PMID:30230171. |
tuberous sclerosis complex (tsc) is a neurocutaneous autosomal-dominant genetic syndrome marked by development of hamartomatous lesions arising from dysfunction of the mammalian target of rapamycin (mtor) pathway. |
2019-09-27 |
2023-08-13 |
Not clear |